| Value | ₹233.5 Cr |
|---|
BSE filing, NSE: SAREGAMA. Summary written from the filing by ALFA Finder's alert engine.
Saregama India Ltd: key numbers
- Share price
- ₹536.00
- Market cap
- ₹10,335 Cr
- Revenue (annual)
- ₹984.6 Cr
- Net profit (annual)
- ₹207.1 Cr
- P/E (TTM)
- 46.8×Sector 28.2×
- Promoter holding
- 60.84%+0.00% QoQ
- FII holding
- 11.88%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saregama India Ltd
All →Saregama India Other Announcement
Saregama India Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure reports the current stake distribution among its shareholders.
Saregama India Employee Stock Options
Saregama India approved the grant of 10,50,000 employee stock options to an eligible employee at an exercise price of Rs. 496.70 per share.
Saregama India Annual General Meeting
Saregama India held its 79th AGM on September 15, 2026, via video conferencing. The meeting covered routine business, including the adoption of financial statements and audit resolutions.
Saregama India Annual General Meeting
Saregama India Limited has issued the notice for its 79th Annual General Meeting scheduled for September 15, 2026. The agenda includes financial statement adoption and director re-appointment.
Saregama India Other Announcement
Saregama India Limited shared the web-link for its FY 2025-26 Integrated Annual Report. The company's 79th Annual General Meeting is scheduled for September 15, 2026.
Saregama India Annual Report
Saregama India Limited has released its Integrated Annual Report for FY 2025-26. The 79th Annual General Meeting is scheduled for September 15, 2026, via video conferencing.
Other credit rating announcements
All →Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.
Adani Ports & Special Economic Zone Credit Rating
Fitch Ratings affirmed Adani Ports' Long-Term Foreign-Currency IDR and unsecured notes at 'BBB-' with a Stable outlook. The affirmation keeps the existing rating unchanged.
Capri Global Capital Credit Rating
India Ratings affirmed CGCL's credit rating at IND AA- with Positive outlook. A new Rs. 500 Cr bank loan facility was also assigned the same rating.